New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer

Rossella Martinello, Sofia Genta, Danilo Galizia, Elena Geuna, Andrea Milani, Giorgia Zucchini, Giorgio Valabrega, Filippo Montemurro

Research output: Contribution to journalReview article

Abstract

Introduction: Endocrine therapy is the mainstay of treatment for a substantial proportion of hormone receptor positive (HR+) breast cancer (BC). Indeed, patients with metastatic disease not immediately life threatening may experience long disease control across several lines of endocrine therapy. The major limitation of this therapeutic approach is primary or acquired resistance. A better understanding of endocrine resistance has resulted in newer targeted agents to be added to endocrine therapy. Areas covered: This review highlights new findings in the treatment of HR+/HER2- BC, with a particular focus on new drugs from phase 3 development onwards. Expert opinion: Combining endocrine therapy with agents targeting putative mechanisms of endocrine resistance is a newer treatment paradigm in HR+ BC. Adding a biologically targeted agent to endocrine therapy results in improved response rate, and clinical benefit rate, and prolonged progression-free survival. A clear advantage in overall survival has not yet been reported. Combination therapy allows to delay chemotherapy but increases toxicities and costs, which are critical factors in decision making in the clinical practice. Moreover, identification and validation of biomarkers of response are needed. Ongoing and future trials should elucidate the role of these compounds in the treatment of HR+/HER2- BC.

Original languageEnglish
Pages (from-to)2179-2189
Number of pages11
JournalExpert Opinion on Pharmacotherapy
Volume17
Issue number16
DOIs
Publication statusPublished - Nov 1 2016

Fingerprint

Hormones
Breast Neoplasms
Drug Therapy
Therapeutics
Expert Testimony
Disease-Free Survival
Biomarkers
Costs and Cost Analysis
Survival
Pharmaceutical Preparations

Keywords

  • Abemaciclib
  • alpelisib
  • buparlisib
  • CDK4/CDK6
  • HDCA
  • HR-positive breast cancer
  • palbociclib
  • PI3K
  • ribociclib
  • taselisib

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer. / Martinello, Rossella; Genta, Sofia; Galizia, Danilo; Geuna, Elena; Milani, Andrea; Zucchini, Giorgia; Valabrega, Giorgio; Montemurro, Filippo.

In: Expert Opinion on Pharmacotherapy, Vol. 17, No. 16, 01.11.2016, p. 2179-2189.

Research output: Contribution to journalReview article

@article{1d2fe3306dce440690eef3f846669794,
title = "New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer",
abstract = "Introduction: Endocrine therapy is the mainstay of treatment for a substantial proportion of hormone receptor positive (HR+) breast cancer (BC). Indeed, patients with metastatic disease not immediately life threatening may experience long disease control across several lines of endocrine therapy. The major limitation of this therapeutic approach is primary or acquired resistance. A better understanding of endocrine resistance has resulted in newer targeted agents to be added to endocrine therapy. Areas covered: This review highlights new findings in the treatment of HR+/HER2- BC, with a particular focus on new drugs from phase 3 development onwards. Expert opinion: Combining endocrine therapy with agents targeting putative mechanisms of endocrine resistance is a newer treatment paradigm in HR+ BC. Adding a biologically targeted agent to endocrine therapy results in improved response rate, and clinical benefit rate, and prolonged progression-free survival. A clear advantage in overall survival has not yet been reported. Combination therapy allows to delay chemotherapy but increases toxicities and costs, which are critical factors in decision making in the clinical practice. Moreover, identification and validation of biomarkers of response are needed. Ongoing and future trials should elucidate the role of these compounds in the treatment of HR+/HER2- BC.",
keywords = "Abemaciclib, alpelisib, buparlisib, CDK4/CDK6, HDCA, HR-positive breast cancer, palbociclib, PI3K, ribociclib, taselisib",
author = "Rossella Martinello and Sofia Genta and Danilo Galizia and Elena Geuna and Andrea Milani and Giorgia Zucchini and Giorgio Valabrega and Filippo Montemurro",
year = "2016",
month = "11",
day = "1",
doi = "10.1080/14656566.2016.1236914",
language = "English",
volume = "17",
pages = "2179--2189",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "16",

}

TY - JOUR

T1 - New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer

AU - Martinello, Rossella

AU - Genta, Sofia

AU - Galizia, Danilo

AU - Geuna, Elena

AU - Milani, Andrea

AU - Zucchini, Giorgia

AU - Valabrega, Giorgio

AU - Montemurro, Filippo

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Introduction: Endocrine therapy is the mainstay of treatment for a substantial proportion of hormone receptor positive (HR+) breast cancer (BC). Indeed, patients with metastatic disease not immediately life threatening may experience long disease control across several lines of endocrine therapy. The major limitation of this therapeutic approach is primary or acquired resistance. A better understanding of endocrine resistance has resulted in newer targeted agents to be added to endocrine therapy. Areas covered: This review highlights new findings in the treatment of HR+/HER2- BC, with a particular focus on new drugs from phase 3 development onwards. Expert opinion: Combining endocrine therapy with agents targeting putative mechanisms of endocrine resistance is a newer treatment paradigm in HR+ BC. Adding a biologically targeted agent to endocrine therapy results in improved response rate, and clinical benefit rate, and prolonged progression-free survival. A clear advantage in overall survival has not yet been reported. Combination therapy allows to delay chemotherapy but increases toxicities and costs, which are critical factors in decision making in the clinical practice. Moreover, identification and validation of biomarkers of response are needed. Ongoing and future trials should elucidate the role of these compounds in the treatment of HR+/HER2- BC.

AB - Introduction: Endocrine therapy is the mainstay of treatment for a substantial proportion of hormone receptor positive (HR+) breast cancer (BC). Indeed, patients with metastatic disease not immediately life threatening may experience long disease control across several lines of endocrine therapy. The major limitation of this therapeutic approach is primary or acquired resistance. A better understanding of endocrine resistance has resulted in newer targeted agents to be added to endocrine therapy. Areas covered: This review highlights new findings in the treatment of HR+/HER2- BC, with a particular focus on new drugs from phase 3 development onwards. Expert opinion: Combining endocrine therapy with agents targeting putative mechanisms of endocrine resistance is a newer treatment paradigm in HR+ BC. Adding a biologically targeted agent to endocrine therapy results in improved response rate, and clinical benefit rate, and prolonged progression-free survival. A clear advantage in overall survival has not yet been reported. Combination therapy allows to delay chemotherapy but increases toxicities and costs, which are critical factors in decision making in the clinical practice. Moreover, identification and validation of biomarkers of response are needed. Ongoing and future trials should elucidate the role of these compounds in the treatment of HR+/HER2- BC.

KW - Abemaciclib

KW - alpelisib

KW - buparlisib

KW - CDK4/CDK6

KW - HDCA

KW - HR-positive breast cancer

KW - palbociclib

KW - PI3K

KW - ribociclib

KW - taselisib

UR - http://www.scopus.com/inward/record.url?scp=84992048122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992048122&partnerID=8YFLogxK

U2 - 10.1080/14656566.2016.1236914

DO - 10.1080/14656566.2016.1236914

M3 - Review article

AN - SCOPUS:84992048122

VL - 17

SP - 2179

EP - 2189

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 16

ER -